CareDx saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 77 to 91.
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the trailing 52 weeks holds up against all the other stocks in our database.
History shows that the best stocks typically have an RS Rating north of 80 in the early stages of their moves.
Here Are 3 Keys For Successful Stock Investing
CareDx has moved more than 5% past a 17.03 entry in a second-stage consolidation, meaning it's now out of a proper buy zone. Look for the stock to offer a new chance to pick up shares like a three-weeks tight or pullback to the 50-day or 10-week line.
CareDx showed 0% earnings growth in the latest quarterly report, while sales growth came in at 32%. The next quarterly results are expected on or around Apr. 30.
The company earns the No. 13 rank among its peers in the Medical-Products industry group. Boston Scientific, Pro-Dex and Axogen are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
